Biophytis SA
ALBPS
Company Profile
Business description
Biophytis SA is a France-based biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Its drug candidate BIO101, is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD.
Contact
BC 9, Batiment A 4eme etage
4 pace Jussieu
Sorbonne University
Paris75005
FRAT: +33 144272300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
24
Stocks News & Analysis
stocks
Tesla’s stock is in trouble, but this fund manager sees a comeback in 2026
Tesla’s challenges echo past issues the company has overcome, says Zevenbergen’s Joe Dennison.
stocks
Cheap ASX energy play boasts strong cash flows and balance sheet
Markets appear overly bearish on the company despite the company having attracting growth options.
stocks
Market overreacts to earnings miss from moated ASX retailer
Our forecast recovery is off to a slow start but the sell-off appears to have gone too far.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,245.00 | 66.30 | -0.71% |
CAC 40 | 7,843.04 | 126.65 | -1.59% |
DAX 40 | 24,273.12 | 89.97 | -0.37% |
Dow JONES (US) | 45,351.92 | 279.82 | -0.61% |
FTSE 100 | 9,321.40 | 12.20 | 0.13% |
HKSE | 25,829.91 | 490.77 | 1.94% |
NASDAQ | 21,524.03 | 27.50 | 0.13% |
Nikkei 225 | 42,807.82 | 174.53 | 0.41% |
NZX 50 Index | 13,079.50 | 36.74 | 0.28% |
S&P 500 | 6,456.22 | 10.69 | -0.17% |
S&P/ASX 200 | 8,972.40 | 71.70 | -0.79% |
SSE Composite Index | 3,883.56 | 57.80 | 1.51% |